Breaking News, Promotions & Moves

Freudenberg Medical Names New CEO

Michael McGee succeeds Dr. Mark Ostwald as chief executive officer.

Effective January 1, 2025, Michael McGee, former COO, has assumed the role of Chief Executive Officer at Freudenberg Medical, succeeding Dr. Mark Ostwald, who transitioned to another leadership role within the Freudenberg Group.

McGee joined Freudenberg Medical as COO in 2022, bringing more than 30 years of experience in the medical device industry. His appointment to CEO reflects Freudenberg’s commitment to continuity and alignment with the company’s values and long-term strategy.

“Since joining Freudenberg Medical, I have been deeply inspired by our company values and our talented global team with proven expertise in materials and technologies. Together, we will build on this strong foundation and drive meaningful advancements in healthcare,” McGee stated. “We remain steadfast in delivering consistent strategic partnership and prioritizing customer success.”

Dr. Mohsen Sohi, Freudenberg Group CEO and Speaker of the Management Board, commented: “Michael has already demonstrated his ability to drive results and success. The Board of Management is confident that under his leadership, Freudenberg Medical will continue to grow, innovate, and thrive.”

This news comes months after Freudenberg Medical expanded its drug device combination products business by investing more than $50 million in a new Hemoteq AG production facility in Aachen, Germany.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters